Ozempic and Wegovy linked to drop in violent behavior, study finds
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Ozempic and Wegovy linked to drop in violent behavior, study finds" is generating significant coverage in the Health category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include CBS News and Healthline. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 107d ago.
Quick answers
Why is "Ozempic and Wegovy linked to drop in violent behavior, study finds" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Rutgers University study connects GLP-1 medications, lower risk of violent behavior CBS News · 149d ago
- Ozempic, Wegovy Linked to Reduced Violent Behavior, Impulsivity Healthline · 149d ago
Topics
Related trends
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.
US regulator orders makers of weight-loss drugs to carry blindness risk warning
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.